| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Mount Sinai Medical Center (Drs. Simpson, Khan, and Godbold, and K. Ebel-Frommer), New York, NY; University of California—San Francisco (Dr. Olney); and Johns Hopkins University (J.C. McArthur), Baltimore, MD.
Address correspondence and reprint requests to Dr. David M. Simpson, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1052, New York, NY 10029; e-mail: david.simpson{at}mssm.edu
OBJECTIVE: To investigate the analgesic efficacy of lamotrigine in the treatment of painful HIV-associated distal sensory polyneuropathy (DSP).
BACKGROUND: The pathogenesis of HIV-associated DSP is unknown and there is no effective treatment. A novel anticonvulsant, lamotrigine, blocks voltage-sensitive sodium channels and inhibits the release of glutamate and aspartate. There have been anecdotal reports of efficacy of lamotrigine in the treatment of painful neuropathy and trigeminal neuralgia.
METHODS: In a multicenter, randomized, double-blind, placebo-controlled study, lamotrigine was initiated at 25 mg per day and slowly titrated over 7 weeks to 300 mg per day. Study duration was 14 weeks. The primary outcome measure was change in pain on the modified Gracely scale with secondary outcome measures including change in neurologic examination, use of concomitant analgesic medications, and global pain relief.
RESULTS: Of 42 enrolled subjects, 13 did not complete the 14-week study endpoint. In five of these, rash was the cause for dropout. In the remaining 29 evaluable subjects, 20 patients received placebo and 9 received lamotrigine. The pain scores at baseline were not significantly different. The reduction in average pain from baseline to week 14 was greater (p = 0.03) in the lamotrigine group (-0.55) than in the placebo group (-0.18), adjusting for baseline levels of pain. There was no difference between the groups on the change in peak worst pain.
CONCLUSIONS: In this small trial, lamotrigine showed promise in the treatment of pain associated with HIV-related DSP. The frequency of rash was greater than in lamotrigine studies in epilepsy. A larger controlled study of lamotrigine is warranted.
Key words: HIV—AIDS—Lamotrigine—Neuropathy.
This article has been cited by other articles:
|
|
 |
|
  D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean Consensus Guidelines: Treatment Planning and Options Mayo Clin. Proc., April 1, 2006; 81(4_Suppl): S12 - S25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Dworkin, J. Katz, and M. J. Gitlin Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology, December 29, 2005; 65(12_suppl_4): S7 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Irving Contemporary assessment and management of neuropathic pain Neurology, June 28, 2005; 64(12_suppl_3): S21 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lussier, A. G. Huskey, and R. K. Portenoy Adjuvant Analgesics in Cancer Pain Management Oncologist, September 1, 2004; 9(5): 571 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Amato and A. L. Oaklander Case 16-2004 - A 76-Year-Old Woman with Numbness and Pain in the Feet and Legs N. Engl. J. Med., May 20, 2004; 350(21): 2181 - 2189. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Dworkin, M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, et al. Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations Arch Neurol, November 1, 2003; 60(11): 1524 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Simpson, J. C. McArthur, R. Olney, D. Clifford, Y. So, D. Ross, B. J. Baird, P. Barrett, A. E. Hammer, and the Lamotrigine HIV Neuropathy Study Team Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial Neurology, May 13, 2003; 60(9): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Mendell and Z. Sahenk Painful Sensory Neuropathy N. Engl. J. Med., March 27, 2003; 348(13): 1243 - 1255. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Evans, B. Fishman, L. Spielman, and A. Haley Randomized Trial of Cognitive Behavior Therapy Versus Supportive Psychotherapy for HIV-Related Peripheral Neuropathic Pain Psychosomatics, February 1, 2003; 44(1): 44 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-M. Backonja Use of anticonvulsants for treatment of neuropathic pain Neurology, September 10, 2002; 59(90052): S14 - 17. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z.-G. Xiong, X.-P. Chu, and J. F. MacDonald Effect of Lamotrigine on the Ca2+-Sensing Cation Current in Cultured Hippocampal Neurons J Neurophysiol, November 1, 2001; 86(5): 2520 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Eisenberg, Y. Lurie, C. Braker, D. Daoud, and A. Ishay Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study Neurology, August 14, 2001; 57(3): 505 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J White Mitochondrial toxicity and HIV therapy Sex Transm Inf, June 1, 2001; 77(3): 158 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vestergaard, G. Andersen, H. Gottrup, B.T. Kristensen, and T.S. Jensen Lamotrigine for central poststroke pain: A randomized controlled trial Neurology, January 23, 2001; 56(2): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Drug treatment of neuropathic pain DTB, December 1, 2000; 38(12): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Kanmaz and N. J. Lee Significant Toxicities Associated with Antiretroviral Therapy Journal of Pharmacy Practice, December 1, 2000; 13(6): 457 - 474. [Abstract] [PDF]
|
|
|
|
|
|
J. R. Berger and A. Nath Remedies for HIV-associated peripheral neuropathy Neurology, June 13, 2000; 54(11): 2037 - 2038. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
